ADC Therapeutics SA (ADCT)
NYSE: ADCT · IEX Real-Time Price · USD
4.100
+0.010 (0.24%)
May 17, 2024, 4:00 PM EDT - Market closed
ADC Therapeutics Revenue
ADC Therapeutics had revenue of $68.62M in the twelve months ending March 31, 2024, down -62.38% year-over-year. Revenue in the quarter ending March 31, 2024 was $18.05M, a -4.94% decrease year-over-year. In the year 2023, ADC Therapeutics had annual revenue of $69.56M, a decrease of -66.86%.
Revenue (ttm)
$68.62M
Revenue Growth
-62.38%
P/S Ratio
5.85
Revenue / Employee
$251,352
Employees
273
Market Cap
401.74M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 69.56M | -140.35M | -66.86% |
Dec 31, 2022 | 209.91M | 175.99M | 518.89% |
Dec 31, 2021 | 33.92M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 2.34M | 1.20M | 105.26% |
Dec 31, 2018 | 1.14M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.78B |
Enhabit | 1.04B |
Bioventus | 522.74M |
Nevro | 430.75M |
Health Catalyst | 296.79M |
Esperion Therapeutics | 229.74M |
C4 Therapeutics | 20.04M |
ADCT News
- 3 days ago - ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 9 days ago - ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 12 days ago - ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants - GlobeNewsWire
- 12 days ago - ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 12 days ago - ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma - GlobeNewsWire
- 17 days ago - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - GlobeNewsWire
- 6 weeks ago - ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma - GlobeNewsWire
- 6 weeks ago - ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 - GlobeNewsWire